Loading...
XNASCLRB
Market cap12mUSD
Dec 26, Last price  
0.30USD
1D
19.29%
1Q
-85.18%
Jan 2017
-99.75%
IPO
-100.00%
Name

Cellectar Biosciences Inc

Chart & Performance

D1W1MN
XNAS:CLRB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
110.43%
Rev. gr., 5y
%
Revenues
0k
12,58400125,96896,31433,334-11,000000000000000
Net income
-38m
L+32.80%
-3,053,399-8,286,056-19,557,135-16,451,406-22,273,3062,095,392-7,435,422-8,796,974-10,782,168-8,106,395-5,495,030-6,180,326-13,562,290-13,239,027-13,874,402-14,756,542-23,970,163-28,601,254-37,983,496
CFO
-32m
L+28.37%
-2,399,097-6,469,425-13,468,299-17,331,895-10,618,338-7,804,283-5,970,090-6,585,024-9,154,644-8,840,479-8,212,980-8,282,218-11,020,301-11,442,092-11,693,708-13,932,743-22,568,838-25,222,301-32,376,974
Earnings
Mar 25, 2025

Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
URL
https://www.cellectar.com/
IPO date
May 20, 2005
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
39,153
29,053
24,359
Unusual Expense (Income)
NOPBT
(39,153)
(29,053)
(24,359)
NOPBT Margin
Operating Taxes
(60)
(60)
(152)
Tax Rate
NOPAT
(39,093)
(28,993)
(24,207)
Net income
(37,983)
32.80%
(28,601)
19.32%
(23,970)
62.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,611
35
BB yield
-79.66%
-0.09%
Debt
Debt current
118
51
135
Long-term debt
1,047
1,157
468
Deferred revenue
Other long-term liabilities
Net debt
(8,400)
(18,659)
(35,100)
Cash flow
Cash from operating activities
(32,377)
(25,222)
(22,569)
CAPEX
(864)
(226)
(141)
Cash from investing activities
(864)
(226)
(141)
Cash from financing activities
22,940
9,611
1,249
FCF
(24,919)
(29,422)
(24,118)
Balance
Cash
9,565
19,866
35,704
Long term investments
Excess cash
9,565
19,866
35,704
Stockholders' equity
(211,423)
(178,117)
(149,515)
Invested Capital
198,258
194,228
182,862
ROIC
ROCE
297.40%
EV
Common stock shares outstanding
12,222
7,056
5,552
Price
2.77
61.99%
1.71
-74.25%
6.64
-68.08%
Market cap
33,854
180.59%
12,065
-67.27%
36,862
-10.55%
EV
31,513
(5,211)
3,144
EBITDA
(38,961)
(28,904)
(24,209)
EV/EBITDA
0.18
Interest
301
Interest/NOPBT